Despite enormous advances in medicine in the 20 th century, diseases caused by microorganisms still represent the highest single cause of mortality worldwide. The majority of deaths are in developing countries but industrialized countries also suffer frequent outbreaks of diseases caused by bacteria and fungi. The problems are exacerbated by the appearance of bacterial strains with increased virulence or enhanced resistance to antibiotics. A staggering 98% of gonococcal isolates in South-East Asia show multidrug resistance and it has been estimated that penicillin resistance in Streptococcus pneumoniae in the USA is at least 40%. Over 50% of hospitalacquired infections in industrialized countries are caused by drugresistant microorganisms.
As Of the initial round of ERA-NET proposals, thirty-two were approved for funding. Although each of the resulting projects focuses on a different scientific area, the overall goals of all ERANETs are highly similar. In a first step a thorough survey of national and international funding activities in the relevant subject area is undertaken. This analysis of the status quo is designed to provide the information required to enable future research activities to be coordinated across national borders. Subsequent work identifies the areas in which transnational cooperation would be most beneficial and attempts to identify opportunities for countries to work together. Attention is also paid to countries outside the EU, such as the USA, Japan and China. ERA-NETs provide opportunities for workshops and exchange programmes to offer training and mobility support for junior researchers. Finally and perhaps most importantly, each ERA-NET should implement one or more joint activities, such as a common call for research proposals. The ultimate hope is that ERA-NETs will pave the way for new transnational funding mechanisms that will enable national systems collectively to take on tasks that they would not have been able to tackle independently.
The importance of coordinating genomic research on diseasecausing microorganisms made the topic a clear choice for the ERA-NET scheme. A group of science ministries and funding agencies from ten countries -Austria, Finland, France, Germany, Hungary, Israel, Latvia, Portugal, Slovenia and Spain -thus joined forces to request funding for such an initiative. Further organizations from Great Britain, Lithuania, Malta, the Netherlands, Norway and Sweden were involved as "affiliated partners". The proposal was extremely positively evaluated and in September the ERA-NET PathoGenoMics was officially launched.
PathoGenoMics now provides a framework for these fifteen countries to work together for the next five years. The program's coordinator, Wilfried Diekmann of the Research Center Jülich, Germany, sees the ERA-NET as a wonderful opportunity. "Germany already has a research programme in the area... and we hope that our experience will be useful to our new partners. We are confident that, with their help, we shall manage to contribute to the development of a European research strategy in the area. All of us stand to gain enormously from the programme."
A further aim of PathoGenoMics is to enhance public awareness of the need for the development of new therapeutic possibilities against pathogenic bacteria. To this end the programme includes a work-package designated 'Science and Society', to be coordinated by Benny Leshem from the Israeli Ministry of Health. "now is the time to show the public what has been done with public funds and to make people understand how vital it is for everybody that we improve our research into the organisms that cause disease." Vicente adds, "We are all talking about the cost of the research... many clinical tests are required before drugs are approved and companies are sometimes reluctant to invest in research to produce something that cures diseases when the alternative is a medicine that must be taken daily and so brings them far greater profits," he says. "But it is important to remember that the current high prevalence of resistance to 'standard' antibiotics is forcing us to use exotic treatments that are many times more expensive. The availability of new and better antimicrobial agents would lead to a dramatic reduction in the cost of health care."
As Philippe Glaser, a scientist at the Institut Pasteur in Paris and a member of the PathoGenomMics executing board puts it, "Genomics and post-genomics offer efficient methods to improve our understanding of pathogenic microorganisms and thus to contribute to the development of more and better methods to combat them."
